Novo Nordisk announced refunds for 340B overcharges on six NDCs including one for Fiasp insulin.

Drug Manufacturer 340B Overcharge Notices Reach New Record, Novo Nordisk Is the Latest

With more than six months to go in the year, the number of refunds that drug manufacturers have had to provide to 340B providers has already topped the previous annual record of 17.  Drug manufacturer Novo Nordisk becomes the 21st manufacturer to post a notice on the U.S. Health Resources and Services Administration website.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report